Bristol-Myers Squibb reports positive data from Yervoy melanoma study

Bristol-Myers Squibb has announced new clinical trial data that demonstrates the strong performance of Yervoy in the treatment of a certain form of melanoma.

Results from the phase III trial CA184-029 showed Yervoy delivered superior efficacy compared to placebo across all survival endpoints among stage III melanoma patients at high risk of recurrence following complete surgical resection.

Yervoy was shown to significantly improve overall survival and distant metastasis-free survival rates, with a recurrence-free survival benefit observed previously with Yervoy maintained over five years.

In stage III melanoma, the disease has not yet spread to distant lymph nodes or other parts of the body, and generally requires surgical resection of the primary tumour as well as the involved lymph nodes.

Dr Vicki Goodman, development lead for melanoma and genitourinary cancers at Bristol-Myers Squibb, said: "With further evaluation of our immuno-oncology agents and different dosing options, we remain committed to further research across the full continuum of melanoma treatment."

The drug is approved for the treatment of unresectable or metastatic melanoma in more than 50 countries, with a broad, ongoing development programme in place assessing the treatment across multiple tumour types.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.